DV-7751a is an investigational fluoroquinolone with improved spectrum and potency against gram-positive bacteria. We studied the in vitro activity of this compound against 771 recent clinical isolates by the reference agar and broth microdilution methods. Its activity was compared with those of ciprofloxacin, levofloxacin, and ofloxacin and with those of ceftazidime, oxacillin, and gentamicin where relevant. DV-7751a was four-to eightfold more active than the comparison fluoroquinolones against Enterococcus spp. (including vancomycinresistant strains), Staphylococcus spp. (including oxacillin-resistant Staphylococcus aureus), Streptococcus spp., other gram-positive pathogens, and some anaerobes. The DV-7751a activity against most gram-negative species was similar to that of ofloxacin and ciprofloxacin. DV-7751a appears to be a candidate for the therapy of some mixed-flora infections and the treatment of bacteria resistant to the current fluoroquinolones.
Fluoroquinolones such as ciprofloxacin and ofloxacin have proved useful in the treatment of a wide variety of infections caused by enteric gram-negative bacilli; however, the frequency of resistance among some species in this group has recently increased (2, 10) . More modest activity against the anaerobes and some pathogenic gram-positive organisms (methicillin-resistant staphylococci and Streptococcus spp.) has limited the use of fluoroquinolone therapy against infections caused by these species as well as for empiric therapy of undiagnosed disease. Resistance to other commonly used antimicrobial agents and the cited decreasing susceptibility to fluoroquinolones have further complicated contemporary infection chemotherapy as follows (5) : (i) high-level resistance to glycopeptides among Enterococcus spp. mediated by vanA vanB genes and marginal activity against the vanC strains has increased (1, 6) ; (ii) oxacillin-resistant strains of Staphylococcus spp. continue at high prevalence in medical centers worldwide, and the frequency of fluoroquinolone susceptibility in this particular population of bacteria has declined (9); (iii) Streptococcus spp. resistant to penicillins, macrolides, and fluoroquinolones continue to emerge; and (iv) anaerobes have become resistant to standard therapies utilized in the past (cephamycins, metronidazole, carbapenems, clindamycin, ␤-lactamase inhibitor combinations). To address the declining spectrum of these cited regimens, new antimicrobial agents must be evaluated for potential use against organisms harboring these resistances, while the range of activity against bacteria with borderline susceptibility must be increased.
DV-7751a is a new fluoroquinolone with potencies similar to those of earlier generation fluoroquinolones against enteric gram-negative bacilli but with enhanced activity against grampositive aerobic bacteria and some anaerobic organisms (7, 8) . It has been found to be bactericidal and has a frequency of spontaneous mutation to resistance equivalent to those of other structurally similar compounds (7, 8) . To further characterize DV-7751a, we have studied its in vitro activity and spectrum against a large collection of recent clinical isolates.
To determine the efficacy of DV-7751a in comparison to related drugs, 771 clinical isolates were collected (from the majority of U.S. states and several other nations) and evaluated by the Anti-Infectives Research Center, University of Iowa College of Medicine, Iowa City. Included in this collection were 251 commonly isolated aerobic and anaerobic grampositive bacterial strains as well as a selected group of vancomycin-resistant Enterococcus faecium isolates with VanA and VanB resistance phenotypes (6) . A total of 520 gram-negative aerobic and anaerobic strains were also tested, including fastidious strains with a variety of beta-lactam resistance mechanisms (see Table 1 ). MICs, with a standardized inoculum, were determined by the broth microdilution method by using an automated instrument (Dynatec Labs Inc., Chantilly, Va.) to inoculate Mueller-Hinton-based microtiter trays (Prepared Media Laboratories, Tualatin, Oreg.) or by the agar dilution method in accordance with the procedures recommended by the National Committee for Clinical Laboratory Standards (NCCLS) (3, 4 cium isolates was greater than those of the other tested fluoroquinolones, with MIC 90 s of 1 and 2 g/ml, respectively. The range of fluoroquinolone activity against E. faecalis and the less frequently isolated Enterococcus spp. (including the VanC resistant phenotype) was more uniform, although the MIC 90 of DV-7751a was consistently twofold lower than that of ciprofloxacin or levofloxacin. DV-7751a activity against oxacillinsusceptible S. aureus and oxacillin-susceptible and -resistant coagulase-negative Staphylococcus spp. was superior to that of the other fluoroquinolones. Among the oxacillin-resistant strains of S. aureus, DV-7751a activity was two-to fourfold greater than that of ciprofloxacin and generally twofold superior to that of levofloxacin and ofloxacin. Cross-resistance among the compared fluoroquinolones was common for all Staphylococcus spp., but all ciprofloxacin-and ofloxacin-resistant strains exhibited lower DV-7751a MICs that ranged from 0.5 to 4 g/ml, e.g., potentially susceptible (MIC Յ 2 g/ml) or intermediately susceptible (MIC ϭ 4 g/ml) by NCCLS interpretive criteria used for similar fluoroquinolones (3). DV-7751a had the lowest MIC range for Bacillus cereus (0.015 to 0.03 g/ml) and was also active against Corynebacterium jeikeium and two strains of Listeria monocytogenes (data not shown). All Streptococcus sp. isolates tested had lower DV-7751a MICs (MIC 90 s, 0.12 to 0.25 g/ml) including those isolates of Streptococcus pneumoniae resistant to penicillin and some comparison fluoroquinolones. Table 1 also lists the comparative activity of DV-7751a for gram-negative organisms. With the exception of Providencia rettgeri and Serratia marcescens, all isolates from the family Enterobacteriaceae were inhibited at achievable clinical concentrations of the four fluoroquinolones. The range of spectrum and potency for DV-7751a against enteric bacilli were most comparable to those of ofloxacin and slightly less than those of ciprofloxacin and levofloxacin. The Acinetobacter spp. were also inhibited by low concentrations of the fluoroquinolones, while Xanthomonas maltophilia, Pseudomonas spp. (including P. aeruginosa), and other nonfermentative gram-negative species were variably susceptible to these compounds, ceftazidime, and gentamicin.
Regardless of the observed ␤-lactamase production, all strains of Moraxella catarrhalis were inhibited by the fluoroquinolones at concentrations of 0.015 to 0.06 g/ml. Haemophilus influenzae and Neisseria spp. showed MICs for ciprofloxacin ranging from 0.004 to 0.12 g/ml, and the DV-7751a MICs ranged from 0.008 to 0.25 g/ml. Resistance mechanisms to beta-lactam drugs also had little influence on the MIC results of DV-7751a among the H. influenzae or pathogenic Neisseria species.
Finally, DV-7751a was compared to ciprofloxacin in susceptibility tests of Bacteroides fragilis, Prevotella spp., and anaerobic gram-positive species. Only one of 40 gram-negative strains was marginally susceptible to ciprofloxacin; however, these strains were marginally inhibited by DV-7751a (MIC 50 s, 0.25 to 1 g/ml). The gram-positive anaerobic organisms, composed of Peptostreptococcus spp. and Clostridium spp. demonstrated only a 65% susceptibility (Յ1 g/ml) rate for ciprofloxacin, while DV-7751a was 4-to Ͼ16-fold more active (MIC 50 comparisons).
The results of this study, pending further human pharmacokinetic data and the establishment of susceptible breakpoint criteria, suggest DV-7751a has the potential to be a broadspectrum fluoroquinolone useful in the treatment of a wide range of clinical infections. The antimicrobial activity of DV7751a presented here compares closely to the earlier results reported by the manufacturer. The key features of this compound appear to be its enhanced activity against gram-positive aerobes and potency against a majority of anaerobic organisms (7). In the study described by Tanaka et al. (7, 8) , MIC 50 s for Enterococcus spp. were 4-to Ͼ16-fold lower with DV-7751a than with other fluoroquinolones. Among ofloxacin-resistant, methicillin-resistant S. aureus isolates, DV-7751a was also consistently more active than levofloxacin, ofloxacin, and ciprofloxacin (7). Gram-negative organisms such as Citrobacter freundii, Proteus vulgaris, and Providencia stuartii were more susceptible to DV-7751a in the present study than were the strains found in Japan (7) .
As microorganisms become more refractory to the antimicrobial agents presently in clinical use, new drugs like DV7751a (7, 8) need to be evaluated as potential therapies against resistant or borderline susceptible isolates. 
